Treatment-Emergent Adverse Events Reported in Placebo-Controlled Trials of Anxiety Disorders

by
ANXIETY DISORDERS
Treatment-Emergent Symptom Incidence* Incidence of Intervention Because of Symptom
Xanax PLACEBO Xanax
*
Events reported by 1% or more of Xanax patients are included.
†
None reported
Number of Patients % of Patients Reporting: 565 505 565
Central Nervous System
Drowsiness 41.0 21.6 15.1
Light-headedness 20.8 19.3 1.2
Depression 13.9 18.1 2.4
Headache 12.9 19.6 1.1
Confusion 9.9 10.0 0.9
Insomnia 8.9 18.4 1.3
Nervousness 4.1 10.3 1.1
Syncope 3.1 4.0 †
Dizziness 1.8 0.8 2.5
Akathisia 1.6 1.2 †
Tiredness/Sleepiness † † 1.8
Gastrointestinal
Dry Mouth 14.7 13.3 0.7
Constipation 10.4 11.4 0.9
Diarrhea 10.1 10.3 1.2
Nausea/Vomiting 9.6 12.8 1.7
Increased Salivation 4.2 2.4 †
Cardiovascular
Tachycardia/Palpitations 7.7 15.6 0.4
Hypotension 4.7 2.2 †
Sensory
Blurred Vision 6.2 6.2 0.4
Musculoskeletal
Rigidity 4.2 5.3 †
Tremor 4.0 8.8 0.4
Cutaneous
Dermatitis/Allergy 3.8 3.1 0.6
Other
Nasal Congestion 7.3 9.3 †
Weight Gain 2.7 2.7 †
Weight Loss 2.3 3.0 †